First Time Loading...

Spero Therapeutics Inc
NASDAQ:SPRO

Watchlist Manager
Spero Therapeutics Inc Logo
Spero Therapeutics Inc
NASDAQ:SPRO
Watchlist
Price: 1.72 USD -1.71% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infec... [ Read More ]

The intrinsic value of one SPRO stock under the Base Case scenario is 17.03 USD. Compared to the current market price of 1.72 USD, Spero Therapeutics Inc is Undervalued by 90%.

Key Points:
SPRO Intrinsic Value
Base Case
17.03 USD
Undervaluation 90%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Spero Therapeutics Inc

Backtest SPRO Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SPRO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Spero Therapeutics Inc's business.

What risks and challenges
does Spero Therapeutics Inc face in the near future?

Summarize the latest earnings report
of Spero Therapeutics Inc.

Provide P/E
for Spero Therapeutics Inc and its competitors.

Financials

Balance Sheet Decomposition
Spero Therapeutics Inc

Current Assets 131.2m
Cash & Short-Term Investments 76.3m
Receivables 50.7m
Other Current Assets 4.2m
Non-Current Assets 51.2m
PP&E 4.2m
Other Non-Current Assets 47m
Current Liabilities 37.2m
Accounts Payable 1.4m
Accrued Liabilities 8.3m
Other Current Liabilities 27.5m
Non-Current Liabilities 38.3m
Other Non-Current Liabilities 38.3m
Efficiency

Earnings Waterfall
Spero Therapeutics Inc

Revenue
103.8m USD
Operating Expenses
-77m USD
Operating Income
26.8m USD
Other Expenses
-4m USD
Net Income
22.8m USD

Free Cash Flow Analysis
Spero Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

SPRO Profitability Score
Profitability Due Diligence

Spero Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional ROIC
Exceptional 1-Year Revenue Growth
ROE is Increasing
41/100
Profitability
Score

Spero Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

SPRO Solvency Score
Solvency Due Diligence

Spero Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
56/100
Solvency
Score

Spero Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SPRO Price Targets Summary
Spero Therapeutics Inc

Wall Street analysts forecast SPRO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SPRO is 7.65 USD with a low forecast of 7.07 USD and a high forecast of 8.4 USD.

Lowest
Price Target
7.07 USD
311% Upside
Average
Price Target
7.65 USD
345% Upside
Highest
Price Target
8.4 USD
388% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

SPRO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

SPRO Price
Spero Therapeutics Inc

1M 1M
+4%
6M 6M
+42%
1Y 1Y
+19%
3Y 3Y
-87%
5Y 5Y
-87%
10Y 10Y
-85%
Annual Price Range
1.72
52w Low
1
52w High
1.95
Price Metrics
Average Annual Return -11.33%
Standard Deviation of Annual Returns 70.13%
Max Drawdown -97%
Shares Statistics
Market Capitalization 91.2m USD
Shares Outstanding 52 999 300
Percentage of Shares Shorted 1.3%

SPRO Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Spero Therapeutics Inc Logo
Spero Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

91.2m USD

Dividend Yield

0%

Description

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. The company is headquartered in Cambridge, Massachusetts and currently employs 146 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). The company is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The firm also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.

Contact

MASSACHUSETTS
Cambridge
675 Massachusetts Ave Ste 14
+18572421600.0
https://sperotherapeutics.com/

IPO

2017-11-02

Employees

146

Officers

Co-Founder & Chairman of the Board
Dr. Ankit Mahadevia M.D., MBA
President, CEO & Director
Mr. Satyavrat Shukla C.F.A.
Chief Legal Officer & Corporate Secretary
Ms. Tamara Lynn Joseph L.L.M.
CFO & Chief Business Officer
Ms. Esther P. Rajavelu
Chief Operating Officer
Mr. Timothy Keutzer
VP & Head of Investor Relations
Ted Jenkins
Show More
Chief Human Resource Officer
Mr. James P. Brady
Chief Medical Officer
Dr. Kamal Hamed M.B.A., M.D., M.P.H.
Show Less

See Also

Discover More
What is the Intrinsic Value of one SPRO stock?

The intrinsic value of one SPRO stock under the Base Case scenario is 17.03 USD.

Is SPRO stock undervalued or overvalued?

Compared to the current market price of 1.72 USD, Spero Therapeutics Inc is Undervalued by 90%.